InspireMD (NSPR) Competitors $2.60 +0.06 (+2.36%) Closing price 04:00 PM EasternExtended Trading$2.59 -0.01 (-0.38%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock NSPR vs. SMTI, RCEL, ZIMV, SNWV, PDEX, NVRO, LUNG, NYXH, CVRX, and ELMDShould you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include Sanara MedTech (SMTI), AVITA Medical (RCEL), ZimVie (ZIMV), SANUWAVE Health (SNWV), Pro-Dex (PDEX), Nevro (NVRO), Pulmonx (LUNG), Nyxoah (NYXH), CVRx (CVRX), and Electromed (ELMD). These companies are all part of the "medical equipment" industry. InspireMD vs. Sanara MedTech AVITA Medical ZimVie SANUWAVE Health Pro-Dex Nevro Pulmonx Nyxoah CVRx Electromed InspireMD (NYSE:NSPR) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Do insiders and institutionals have more ownership in NSPR or SMTI? 44.8% of InspireMD shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 29.7% of InspireMD shares are owned by insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in NSPR or SMTI? Sanara MedTech received 19 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 60.53% of users gave Sanara MedTech an outperform vote while only 4.04% of users gave InspireMD an outperform vote. CompanyUnderperformOutperformInspireMDOutperform Votes44.04%Underperform Votes9595.96% Sanara MedTechOutperform Votes2360.53% Underperform Votes1539.47% Which has higher earnings and valuation, NSPR or SMTI? Sanara MedTech has higher revenue and earnings than InspireMD. Sanara MedTech is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$7.01M11.36-$19.92M-$0.78-3.33Sanara MedTech$86.67M3.31-$4.30M-$1.14-28.28 Which has more volatility and risk, NSPR or SMTI? InspireMD has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Is NSPR or SMTI more profitable? Sanara MedTech has a net margin of -10.71% compared to InspireMD's net margin of -413.96%. Sanara MedTech's return on equity of -19.86% beat InspireMD's return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% Sanara MedTech -10.71%-19.86%-10.91% Does the media prefer NSPR or SMTI? In the previous week, InspireMD had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for InspireMD and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.75 beat InspireMD's score of 0.82 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Overall Sentiment InspireMD Positive Sanara MedTech Very Positive Do analysts rate NSPR or SMTI? InspireMD presently has a consensus target price of $4.75, suggesting a potential upside of 82.69%. Sanara MedTech has a consensus target price of $48.50, suggesting a potential upside of 50.43%. Given InspireMD's higher possible upside, analysts plainly believe InspireMD is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sanara MedTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySanara MedTech beats InspireMD on 10 of the 16 factors compared between the two stocks. Get InspireMD News Delivered to You Automatically Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NSPR vs. The Competition Export to ExcelMetricInspireMDSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$79.65M$4.33B$5.47B$18.90BDividend YieldN/A39.93%5.11%4.01%P/E Ratio-3.4730.0322.5132.87Price / Sales11.3655.31397.6228.03Price / CashN/A51.0838.1817.52Price / Book1.426.056.734.47Net Income-$19.92M$68.71M$3.22B$1.02B7 Day PerformanceN/A0.05%1.58%0.73%1 Month Performance2.36%-2.15%4.05%-2.62%1 Year Performance32.65%22.61%15.75%4.59% InspireMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NSPRInspireMD2.3264 of 5 stars$2.60+2.4%$4.75+82.7%+30.9%$79.65M$7.01M-3.4750News CoverageSMTISanara MedTech2.0281 of 5 stars$31.64-0.3%$48.50+53.3%+0.3%$281.22M$86.67M-31.9660News CoverageRCELAVITA Medical1.6922 of 5 stars$10.25+1.8%$17.25+68.3%+15.4%$270.96M$64.25M-4.29130Upcoming EarningsPositive NewsZIMVZimVie2.4918 of 5 stars$9.31-1.4%$19.50+109.5%-40.4%$259.26M$449.75M-0.712,700Positive NewsSNWVSANUWAVE HealthN/A$27.40-3.8%N/AN/A$234.24M$32.63M-7.0340High Trading VolumePDEXPro-Dex1.4213 of 5 stars$69.00+6.3%$52.00-24.6%+255.0%$225.01M$61.00M34.33140Earnings ReportShort Interest ↑News CoverageHigh Trading VolumeNVRONevro0.1892 of 5 stars$5.85+0.1%$5.36-8.3%-44.7%$224.32M$408.52M-3.091,090Upcoming EarningsAnalyst ForecastLUNGPulmonx3.736 of 5 stars$5.19-0.2%$12.75+145.7%-36.5%$208.88M$83.79M-3.60250Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap UpNYXHNyxoah2.2865 of 5 stars$6.01+2.4%$14.50+141.3%-41.0%$204.70M$4.52M-3.21110CVRXCVRx3.1142 of 5 stars$7.52+11.7%$16.83+123.8%-52.8%$195.79M$51.29M-2.80160Upcoming EarningsShort Interest ↓News CoveragePositive NewsHigh Trading VolumeELMDElectromed0.6164 of 5 stars$22.87-0.8%$38.00+66.2%+32.4%$195.70M$59.63M30.49160Analyst Upgrade Related Companies and Tools Related Companies SMTI Competitors RCEL Competitors ZIMV Competitors SNWV Competitors PDEX Competitors NVRO Competitors LUNG Competitors NYXH Competitors CVRX Competitors ELMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NSPR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NSPR Stock Free NSPR Stock Alerts